间充质干细胞作为对抗氧化应激介导的神经性疼痛的治疗策略。

IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY
Bioimpacts Pub Date : 2025-01-05 eCollection Date: 2025-01-01 DOI:10.34172/bi.30648
Aidin Shahrezaei, Maryam Sohani, Farinaz Nasirinezhad
{"title":"间充质干细胞作为对抗氧化应激介导的神经性疼痛的治疗策略。","authors":"Aidin Shahrezaei, Maryam Sohani, Farinaz Nasirinezhad","doi":"10.34172/bi.30648","DOIUrl":null,"url":null,"abstract":"<p><p>Neuropathic pain, a chronic condition resulting from somatosensory system damage, remains a significant clinical challenge due to its complex pathophysiology and inadequate response to traditional therapies. Oxidative stress, characterized by an imbalance between free radicals production and antioxidant defenses, plays a pivotal role in the development and maintenance of neuropathic pain. Mesenchymal stem cells (MSCs) are multipotent stromal cells with the ability to differentiate into various cell types and possess immunomodulatory, anti-inflammatory, and regenerative properties, making them promising candidates for novel pain management strategies. Preclinical studies demonstrate that MSCs can reduce inflammation, scavenge reactive oxygen species (ROS), promote nerve regeneration, and modulate pain signaling pathways. Various administration routes, including intravenous and intrathecal, have been investigated to optimize MSC delivery and efficacy. Additionally, MSC-derived extracellular vesicles (EVs) represent a cell-free alternative with substantial therapeutic potential. Despite encouraging preclinical findings, further research is needed to refine MSC-based therapies, including the exploration of combination treatments and rigorous clinical trials, to translate these promising results into effective clinical applications for neuropathic pain relief. This review explores the therapeutic potential of MSCs in alleviating oxidative stress-mediated neuropathic pain.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30648"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008502/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mesenchymal stem cells as a therapeutic strategy to combat oxidative stress-mediated neuropathic pain.\",\"authors\":\"Aidin Shahrezaei, Maryam Sohani, Farinaz Nasirinezhad\",\"doi\":\"10.34172/bi.30648\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neuropathic pain, a chronic condition resulting from somatosensory system damage, remains a significant clinical challenge due to its complex pathophysiology and inadequate response to traditional therapies. Oxidative stress, characterized by an imbalance between free radicals production and antioxidant defenses, plays a pivotal role in the development and maintenance of neuropathic pain. Mesenchymal stem cells (MSCs) are multipotent stromal cells with the ability to differentiate into various cell types and possess immunomodulatory, anti-inflammatory, and regenerative properties, making them promising candidates for novel pain management strategies. Preclinical studies demonstrate that MSCs can reduce inflammation, scavenge reactive oxygen species (ROS), promote nerve regeneration, and modulate pain signaling pathways. Various administration routes, including intravenous and intrathecal, have been investigated to optimize MSC delivery and efficacy. Additionally, MSC-derived extracellular vesicles (EVs) represent a cell-free alternative with substantial therapeutic potential. Despite encouraging preclinical findings, further research is needed to refine MSC-based therapies, including the exploration of combination treatments and rigorous clinical trials, to translate these promising results into effective clinical applications for neuropathic pain relief. This review explores the therapeutic potential of MSCs in alleviating oxidative stress-mediated neuropathic pain.</p>\",\"PeriodicalId\":48614,\"journal\":{\"name\":\"Bioimpacts\",\"volume\":\"15 \",\"pages\":\"30648\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008502/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioimpacts\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.34172/bi.30648\",\"RegionNum\":4,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioimpacts","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.34172/bi.30648","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

神经性疼痛是一种由体感觉系统损伤引起的慢性疾病,由于其复杂的病理生理和对传统疗法的反应不足,仍然是一个重大的临床挑战。氧化应激以自由基产生和抗氧化防御之间的不平衡为特征,在神经性疼痛的发生和维持中起着关键作用。间充质干细胞(MSCs)是一种多能基质细胞,具有分化成各种细胞类型的能力,并具有免疫调节、抗炎和再生特性,使其成为新型疼痛治疗策略的有希望的候选者。临床前研究表明,间充质干细胞可以减少炎症,清除活性氧(ROS),促进神经再生,调节疼痛信号通路。研究了多种给药途径,包括静脉注射和鞘内注射,以优化MSC的给药和疗效。此外,msc衍生的细胞外囊泡(EVs)代表了一种具有巨大治疗潜力的无细胞替代品。尽管临床前研究结果令人鼓舞,但需要进一步研究以完善基于msc的治疗方法,包括探索联合治疗和严格的临床试验,将这些有希望的结果转化为有效的临床应用,以缓解神经性疼痛。这篇综述探讨了MSCs在缓解氧化应激介导的神经性疼痛方面的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mesenchymal stem cells as a therapeutic strategy to combat oxidative stress-mediated neuropathic pain.

Neuropathic pain, a chronic condition resulting from somatosensory system damage, remains a significant clinical challenge due to its complex pathophysiology and inadequate response to traditional therapies. Oxidative stress, characterized by an imbalance between free radicals production and antioxidant defenses, plays a pivotal role in the development and maintenance of neuropathic pain. Mesenchymal stem cells (MSCs) are multipotent stromal cells with the ability to differentiate into various cell types and possess immunomodulatory, anti-inflammatory, and regenerative properties, making them promising candidates for novel pain management strategies. Preclinical studies demonstrate that MSCs can reduce inflammation, scavenge reactive oxygen species (ROS), promote nerve regeneration, and modulate pain signaling pathways. Various administration routes, including intravenous and intrathecal, have been investigated to optimize MSC delivery and efficacy. Additionally, MSC-derived extracellular vesicles (EVs) represent a cell-free alternative with substantial therapeutic potential. Despite encouraging preclinical findings, further research is needed to refine MSC-based therapies, including the exploration of combination treatments and rigorous clinical trials, to translate these promising results into effective clinical applications for neuropathic pain relief. This review explores the therapeutic potential of MSCs in alleviating oxidative stress-mediated neuropathic pain.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bioimpacts
Bioimpacts Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.80
自引率
7.70%
发文量
36
审稿时长
5 weeks
期刊介绍: BioImpacts (BI) is a peer-reviewed multidisciplinary international journal, covering original research articles, reviews, commentaries, hypotheses, methodologies, and visions/reflections dealing with all aspects of biological and biomedical researches at molecular, cellular, functional and translational dimensions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信